Sign In
IMMU.US
id: 350
It is still possible to file a late claim. The court will decide whether to accept late claims or not.
D. New Jersey
Court
02 May 2016
Class period Start
24 Jun 2016
Class period End
06 Dec 2022
Claim deadline
Sensung Tsai, et al. v. Immunomedics, Inc., et al.

Immunomedics (IMMU) agreed to pay $4 million to settle a securities class action lawsuit.

The Complaint alleged that the Company and its Leaders made false and/or misleading statements and/or failed to disclose that:
  • the abstract for IMMU-132 that Immunomedics submitted to the American Society of Clinical Oncology (“ASCO”) for presentation at the 2016 ASCO Annual Meeting contained previously disclosed results from a mid-stage study;
  • Immunomedics had misrepresented to ASCO that its abstract for IMMU-132 contained only updated and previously undisclosed data;
  • the foregoing misrepresentation was a violation of ASCO policy and made Immunomedics’ IMMU-132 presentation subject to removal from the 2016 ASCO Annual Meeting schedule.
Immunomedics (IMMU) agreed to settle with investors to avoid further litigation.
Alleged Offence
Other
Suspected Party
Other
Security Type
Stocks
Trade Direction
Long
Plaintiffs
Sensung Tsai
Attorneys
Hagens Berman Sobol Shapiro LLP (Berkeley, CA) Lite DePalma Greenberg, LLC (Newark, NJ)
Judge
Hon. Katharine S. Hayden
Administrator
Strategic Claims Services
Court hearing date
19 January 2023
+$4,000,000
Total Settlement Amount

Immunomedics, Inc.

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug...

    Ticker
    IMMU.US
    ISIN
    US4529071080
    CIK
    722830
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    300 The American Road, Morris Plains, NJ, United States, 07950